Navigation Links
Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease

Studies in Mice Show Reduction of Enzyme Substrate

CRANBURY, N.J., March 19, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present results from studies of Amigal(TM) (migalastat hydrochloride, AT1001), Amicus' compound in development for the treatment of Fabry disease, at the of Medical Genetics (ACMG) Annual Meeting from March 21-25 in Nashville, TN. This presentation will include the first data from the Company demonstrating the reduction of globotriaosylceramide (GL-3), the lipid substrate that accumulates in Fabry disease, after oral administration of a pharmacological chaperone. These data were not available at the time of abstract submission but will be included in the presentation at the meeting.

Amigal is designed to selectively bind to and stabilize alpha- galactosidase A (alpha-GAL), the enzyme deficient in Fabry disease. This deficiency leads to lysosomal accumulation of GL-3, which is believed to cause the various symptoms of Fabry disease. Amigal facilitates proper trafficking of the enzyme to the lysosomes, the compartments in the cell where it is needed to break down GL-3.

At the ACMG meeting, Amicus scientists will present data from several studies that examined the in vitro and in vivo effects of Amigal in cell lines, mice and healthy volunteers. Among the key findings:

    - In vitro exposure to Amigal increased the level of alpha-GAL in cells

      derived from healthy volunteers and from Fabry patients.

    - Oral administration of Amigal resulted in a dose-dependent increase in

      alpha-GAL levels in various tissues of normal mice and Fabry mice

      genetically modified to produce alpha-GAL with a human missense


    - Oral administration of Amigal to healthy vo
lunteers in a Phase 1

      clinical study resulted in a dose-dependent increase of alpha-GAL levels

      in white blood cells.

    - Oral administration of Amigal significantly decreased the level of GL-3

      in the skin and heart of Fabry mice and showed a trend towards reduction

      in the kidney.

    About Fabry Disease

Fabry disease is a lysosomal storage disorder caused by inherited genetic mutations in the GLA gene, which result in deficient activity of the enzyme alpha-galactosidase A (alpha-GAL). Deficient alpha-GAL activity leads to lysosomal accumulation of globotriaosylceramide (GL-3), which is believed to cause the various symptoms of Fabry disease, including pain, kidney failure and increased risk of heart attack and stroke. Fabry disease is estimated to affect approximately 5,000 to 10,000 people in the developed world, but recent evidence suggests that the disease may be significantly underdiagnosed. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan designation for Amigal in the United States, and the European Commission has designated Amigal as an orphan medicinal product in the European Union.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus is currently conducting Phase 2 clinical trials for its two lead compounds, Amigal(TM) for Fabry disease, and AT2101 for Gaucher disease. The company is currently conducting Phase 1 trials with AT2220 for the treatment of Pompe disease.

CONTACT: Corporate: Matthew Patterson, Amicus Therapeutics,+1-609-662-2000, or Media: Dan Budwick, BMC Communications Group,+1-212-477-9007 ext. 14

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:10/8/2015)... Oct. 9, 2015 Johnson & Johnson (NYSE: ... immunogenicity clinical trial in Sierra Leone ... Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first ... first study conducted of Janssen,s Ebola prime-boost vaccine regimen in ... Sierra Leone,s Kambia district, where ...
(Date:10/8/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a ... diseases, today announced that clinical data for the ... at the 2015 American College of Gastroenterology (ACG) ... sustained response in IBS-C patients enrolled in the ... trial. The meeting will be held in ...
(Date:10/8/2015)... SAN DIEGO , Oct. 8, 2015 /PRNewswire/ ... cell-free molecular diagnostics, today announced the presentation of ... use of its Precision Cancer Monitoring SM ... can be critical for physicians to determine appropriate ... chief scientific officer of Trovagene is delivering the ...
Breaking Medicine Technology:
... February is American Heart Month and a time when ... on their family history of heart disease and recommit ... teaming up with the makers of Bayer® Aspirin and ... to raise $100,000 for the fight against heart disease. ...
... 2012 Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ... the Leerink Swann 2012 Global Healthcare Conference to be ... New York City.  Mr. Adrian Adams, Chief Executive Officer ... the Company and its product pipeline at 10:30 a.m. ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... Well-known Eastern ... to be recognized by The National Law Journal for inclusion in their second ... firms across the United States who obtained the largest awards for their personal ...
(Date:10/9/2015)... California (PRWEB) , ... October 09, 2015 , ... ... Osteopathic Medicine of the Pacific Associate Dean for Graduate Medical Education J. Michael ... of the Year Award. Finley was selected for his impact on graduate medical ...
(Date:10/9/2015)... ... October 09, 2015 , ... With the FCPX LUT Vibrance pack from ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. This pack comes with 60 vibrant CUBE LUT files. , Inspired ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In fact, ... risk of dying in reported home fires in half. As part of Fire Prevention ... are property installed and maintained. , Half of home fire deaths result from fires ...
(Date:10/9/2015)... ... , ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend the ... in Huntsville, Texas on October 17-21. , "It's very exciting to be invited ... executive director, said. “It's a stepping stone into the U.S. elite system where Maddie ...
Breaking Medicine News(10 mins):
... Neuroscientists at MIT,s Picower Institute of Learning and Memory have ... inexplicably linked to long-term memories. The work is slated to ... "Our finding explains, at least partially, why seemingly irrelevant ... person is remembered as vividly as more significant information such ...
... HealthDay Reporter , THURSDAY, Jan. 13 (HealthDay News) -- This winter ... instead is turning out to be a more typical flu season, ... to get a flu shot, advice that seniors in particular should ... their age group the hardest, the experts added. The H1N1 flu ...
... for Injury Biomechanics ( ) has been awarded ... Research and Materiel Command for phase 2 of an ... military personnel. Specifically, blast induced brain trauma will be ... helmet design and body armor and the resulting reductions ...
... Liverpool-led consortium has received $1.5million from the Bill & ... serious disease and epidemics in sub-Saharan Africa. Streptococcus ... in sub-Sahara Africa. The funding will enable scientists ... associated with invasive pneumococcal disease, why it spreads so ...
... HealthDay Reporter , THURSDAY, Jan. 13 (HealthDay ... by patients and health professionals alike to save money ... and potentially dangerous, a new study suggests. Belgian ... deviated from recommended dosages by 15 percent or more. ...
... HealthDay Reporter , WEDNESDAY, Jan. 12 (HealthDay News) -- ... said Tuesday, breathing on her own and moving both arms ... "She has a 101 percent chance of surviving," Dr. ... told the Associated Press . "She will not die." ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: